KeyaMed NA

Company profile

About KeyaMed NA

Keya Medical is a medical artificial intelligence company specializing in deep learning solutions for cardiovascular imaging and diagnostics. Founded in 2016 as CuraCloud in Seattle, the company initially focused on AI algorithms for medical imaging and bioinformatics, achieving early success with FDA-cleared software for triaging intracranial hemorrhage from head CT scans. In 2020, the company rebranded as Keya Medical and expanded its focus to AI-driven cardiovascular imaging. Headquartered in Seattle, Washington, and Shenzhen, China, Keya Medical operates across Asia, Europe, and North America. The company's primary offering is DEEPVESSEL FFR, an AI-enabled, non-invasive CT fractional flow reserve (FFR-CT) analysis tool that provides physiological functional assessment of coronary arteries using coronary computed tomography angiograms. This technology helps clinicians reduce unnecessary invasive testing, improve patient safety, and lower cardiovascular testing costs. DEEPVESSEL FFR has achieved regulatory clearance in multiple markets: CE-marked in 2018, NMPA-approved in China in 2020, FDA-cleared in 2022, and HSA-certified in Singapore in 2023. The company also offers DEEPVESSEL Plaque for quantitative plaque analysis, currently available for research use only in the United States. Keya Medical's solutions are designed to support confident clinical decision-making from a single CCTA examination, combining advanced deep learning technology with streamlined workflow integration. The company has been featured at major international cardiovascular and imaging conferences including SCCT, ECR, and RSNA.

Company description · KeyaMed NA official website